Neurodegeneration
Using Virtual Reality to Detect Early Alzheimer's Disease
Open access · cc by · source: Europe PMC
A virtual reality walking test assessing entorhinal cortex function accurately identifies patients with early-stage, biomarker-proven Alzheimer's disease.
Study at a glance
- Design
- Cross-sectional — Immersive VR navigation test comparing biomarker-defined MCI patients and healthy controls
- N
- N=86 · 45 MCI patients (12 biomarker-positive, 14 biomarker-negative among CSF-tested) and 41 healthy controls
- Population
- Mild cognitive impairment patients and healthy controls performing entorhinal-based VR navigation
- Outcome
- Navigation error distinguishing biomarker-positive early Alzheimer’s MCI from biomarker-negative MCI and controls
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
MCI patients as a whole had larger navigation errors than controls, showing an average increase of 57.33 centimeters in distance error. Crucially, biomarker-positive MCI patients performed significantly worse than biomarker-negative patients, with an additional error increase of 97.56 centimeters. The virtual reality test distinguished biomarker-positive MCI from biomarker-negative MCI with a high classification accuracy (an area under the curve of 0.90), vastly outperforming standard cognitive tests.
Methodology
Researchers tested whether an immersive virtual reality navigation task could identify mild cognitive impairment (MCI) patients at risk of Alzheimer's disease. The study included 45 MCI patients—some of whom were classified as biomarker-positive (12 patients) or biomarker-negative (14 patients) via spinal fluid tests—and 41 healthy control subjects. Participants wore a virtual reality headset and walked a path with three marker cones in a physical room, completing 27 trials where they had to return to the spot of the first cone without visual cues.
Limitations
The study is limited by its small sample sizes, particularly in the biomarker-verified groups which only contained 12 biomarker-positive and 14 biomarker-negative patients. Furthermore, physical space constraints led to a loss of data, with 33.77% of trials excluded because participants walked past the designated boundaries. Finally, because the link between brain volumes and navigation errors is purely correlational, the design cannot conclusively prove that entorhinal degeneration directly caused the observed navigation errors.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
A VR navigation task can separate biomarker-positive MCI from controls.
An entorhinal-cortex–based virtual navigation task produced larger path errors in MCI than controls, with biomarker-positive MCI performing worse than biomarker-negative MCI—linking a behavioural assay to CSF Alzheimer’s markers.
Evidence for the claim as stated.
VR navigation separates biomarker-defined MCI behaviourally; CSF tau in unimpaired adults tracks hippocampal hyperactivity and object memory. Shared theme: early Alzheimer’s biology can show up before frank dementia—different tasks, samples, and endpoints.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
VR navigation separates biomarker-defined MCI behaviourally; CSF tau in unimpaired adults tracks hippocampal hyperactivity and object memory. Shared theme: early Alzheimer’s biology can show up before frank dementia—different tasks, samples, and endpoints.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- How tau buildup shapes brain networks in dementia
- How does brain structure change in early Parkinson's disease?
- How does brain inflammation affect connectivity and thinking in AD?
- Can a new PET imaging tracer distinguish different tau diseases?
- Does brain region loss predict memory decline in Parkinson's?